Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I/ Phase II
Recipient : Entheon Biomedical
Deal Size : Not Applicable
Deal Type : Not Applicable
Entheon Biomedical Provides Update on Clinical and Preclinical DMT Programs
Details : Formulation and stability testing of DMT drug product by CHDR's partner pharmacy has commenced in accordance with projected start date of EBRX-101(N, N-dimethyltryptamine), a study that will evaluate controlled intravenous infusion of population of healt...
Brand Name : EBRX-101
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 24, 2021
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I/ Phase II
Recipient : Entheon Biomedical
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?